If your patient is on a GLP-1 and needs an opioid, oxycodone is the wrong one

Design

population-based new-user cohort study using US insurance claims 2016-2025, propensity score-matching weights, 30-day outcome window

Population

411,188 adults with type 2 diabetes on GLP-1 receptor agonist therapy initiating oxycodone, hydrocodone or tramadol; mean age 62.8, 53.8% female

Primary outcome

composite of motility-related gastrointestinal events — severe constipation, bowel obstruction and gastroparesis — at 30 days

Effect

absolute risk 0.51% oxycodone, 0.35% hydrocodone, 0.33% tramadol; oxycodone vs hydrocodone RR 1.48 (95% CI 1.30-1.69), vs tramadol RR 1.55 (1.33-1.79)

GLP-1 receptor agonists slow gastric emptying and gut transit; so do opioids. That interaction had not been characterised, and this new-user cohort study addresses it directly, using US insurance claims from 2016 to 2025 and propensity score-matching weights. Among 411,188 adults with type 2 diabetes on a GLP-1 receptor agonist who then started an opioid — 24.4% oxycodone, 48.5% hydrocodone, 27.1% tramadol — the outcome was a 30-day composite of severe constipation, bowel obstruction and gastroparesis.

Weighted 30-day absolute risk was 0.51% with oxycodone, 0.35% with hydrocodone and 0.33% with tramadol. Oxycodone carried a higher risk than hydrocodone (RR 1.48, 95% CI 1.30 to 1.69; risk difference 0.17 percentage points, 95% CI 0.11 to 0.22) and than tramadol (RR 1.55, 95% CI 1.33 to 1.79; risk difference 0.18, 95% CI 0.12 to 0.24). Hydrocodone and tramadol were indistinguishable (RR 1.05, 95% CI 0.91 to 1.21). The gastroparesis component alone did not differ; the signal is in constipation and obstruction.

Keep the absolute numbers in view: this is a difference of about 1.7 extra events per 1,000 patients over 30 days, so nobody should be denied adequate analgesia over it. What it does justify is a default. Where the opioids are otherwise interchangeable for the indication — and for most short courses they are — choose the one without the extra risk, and prescribe a laxative alongside rather than waiting to be asked. Where oxycodone is genuinely the right drug, the study tells you what to warn about and what to review at two weeks.

• Prefer tramadol or hydrocodone over oxycodone for a short opioid course in a patient on a GLP-1 receptor agonist, where the indication allows
• Co-prescribe a laxative at the point of starting any opioid in this group, not reactively
• Warn explicitly about absolute constipation and abdominal distension, and review at two weeks
• Keep the size in proportion — about 1.7 extra events per 1,000 over 30 days; do not undertreat pain
• Tramadol carries its own cautions in diabetes, including hypoglycaemia and seizure risk, and interacts with serotonergic drugs

The statistics, in plain English

The relative risks (1.48 and 1.55) sound large while the risk difference is 0.17 to 0.18 percentage points, because the baseline event rate is under 1% — always read both together. This is claims-based and observational, so despite propensity weighting, the reasons a clinician chose oxycodone rather than tramadol may themselves predict gut complications; a new-user design with a short 30-day window limits but does not eliminate that. The null result for hydrocodone versus tramadol (0.91 to 1.21) is a genuinely tight interval and supports real equivalence rather than mere absence of power.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.